[Skip to Navigation]
Viewpoint
November 8, 2018

Is Precision Medicine an Oxymoron?

Author Affiliations
  • 1LiveSTRONG Cancer Institutes, Dell Medical School, The University of Texas at Austin
  • 2Division of Medical Oncology, University of Colorado Denver, Aurora
JAMA Oncol. 2019;5(2):142-143. doi:10.1001/jamaoncol.2018.5099

The initial results of the National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) trial were presented at the 2018 American Society of Clinical Oncology Annual Meeting. The NCI-MATCH trial is an ongoing phase 2 trial that seeks to determine whether targeted therapies for specific gene mutations will lead to objective responses agnostic to the primary cancer type. The trial features nearly 40 treatment arms, each of which aims to enroll at least 35 patients whose tumors have a specific genetic alteration. Individual arms rely on objective response as the primary end point, which also drives decisions about expansion beyond the first stage of accrual. Additional arms in the NCI-MATCH trial are currently enrolling, and several are in development.

×